Timeframe: 2020 – 2023 Goal: Create a comprehensive list of potential drug targets for FLC Principal Investigator: Jesse Boehm, PhD Study overview: This project is part of the Broad Institute’s Rare Cancer Dependency Map Initiative. The project has three main goals to identify potential FLC therapeutics: If fully successful, this effort will nominate high priority …
Timeframe: 2022 – 2023 Goal: Development of a novel human-derived liver progenitor cell line model of fibrolamellar carcinoma Principal Investigator: Khashayar Vakili, MD Study overview: Currently, very few cell-line models of FLC exist, so the development of additional cellular models is critical for the identification and testing of new therapies. Therefore, one of the aims …
Timeframe: 2025 – 2026 Goal: Model development Principal Investigator: Nabeel Bardeesy, PhD Study overview: Cell line models and patient-derived xenographs (PDXs) are important tools that researchers can use to study disease. For FLC research to move forward, stable, reliable,patient-derived cell lines that truly represent the human disease are needed. While multiple FLC models have recently …
Timeframe: 2024 – 2025 Goals: Model development Principal Investigators: Aleksander Skardal, PhD Study overview: While researchers have made progress in treating fibrolamellar carcinoma (FLC), a big challenge remains – scientists do not have good lab models that mimic the real disease. Right now, there are very few FLC cell lines, patient-derived xenografts (PDX), or other …
Timeframe: 2023 – 2025 Goals: Model development and understanding the requirements for FLC tumor formation Principal Investigators: Benedetta Artegiani, PhD; and Delilah Hendriks, PhD Study overview: In comparison with more common cancers, research models of FLC have been extremely limited. Drs. Artegiani and Hendriks have addressed this problem by creating “synthetic” models of FLC, generating …
Timeframe: 2023 – 2024 Goal: Immunocompetent mouse model development Principal Investigator: Julien Sage, PhD Study overview: Dr. Julien Sage has a very longstanding interest in FLC and is recognized as a world leader in the type of genetic modeling in mice proposed in this study. This study proposes to extend Dr. Sage’s team’s previous work …
Timeframe: 2021 – 2023 Goal: Develop a blood-based screening method to detect relapse in FLC patients Principal Investigator: Gary S. Stein, PhD Study overview: This study is focused on developing a blood-based screening method to detect relapse in FLC patients that have been diagnosed and treated by surgery. This screening protocol is intended to be …
Timeframe: 2012 – 2013 Goal: Support series of projects exploring the role of antibody involvement in FLC tumors Principal Investigator: Sandy Simon, PhD Study overview: This effort continued the encouraging early work begun on mice to see if researchers could take advantage of the immune system to identify potential ways to detect and eventually treat …
Timeframe: 2010 – 2011 Goal: Build understanding of the immunology and cell biology of FLC using mouse models of cancer Principal Investigator: Sandy Simon, PhD Study background: This early study was designed to determine if researchers could take advantage of the immune system to identify potential ways to detect and eventually treat fibrolamellar. The immune …